Research programme: PCSK9 protein inhibitor - Serometrix
Latest Information Update: 07 Mar 2024
At a glance
- Originator Serometrix
- Developer Esperion Therapeutics; Serometrix
- Class Small molecules
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypercholesterolaemia
Most Recent Events
- 05 Aug 2023 Esperion Therapeutics terminates licensing agreement with Serometrix for oral PCSK9 inhibitor programme
- 08 May 2023 Esperion therapeutics announces intention to file an IND application for Hypercholesterolaemia in late 2024 or early 2025
- 31 Dec 2020 Esperion Therapeutics in-licenses Serometrix's oral PCSK9 inhibitor programme